Clinical Phase I Investigation of Intravenous Oil Attached Mycobacterial Components as Immunotherapeutic Agents

  • Gerald Vosika
  • Tim Trenbeath
  • Cathy Giddings
  • Gary R. Gray
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 166)


Nonspecific immunostimulation with mycobacterial agents, especially BCG, have been widely utilized (1) in an effort to increase host resistance to malignancy. Crude viable and/or killed mycobacterial agents are heterogenous preparations (2, 3), which have a significant incidence of morbidity. From an immunotherapeutic viewpoint, BCG has been shown (4, 5), in high doses, to cause splenic suppressor cells in mice, and has been implicated in causing tumor enhancement (6). Because of these problems, major interest has centored on the purification and use of microbial components.


Mycobacterium Smegmatis Cancer Immunol Tumor Enhancement Immunotherapeutic Agent Cell Wall Skeleton 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bast, R. C., B. Zbar, T. Boros, and H. G. Rapp. 1974. BCG and cancer. N. Engl. J. Med. 290: 1413–1419.PubMedCrossRefGoogle Scholar
  2. 2.
    Aungst, C. W., J. E. Sokol, and B. V. Jager. 1975. Complications of BCG vaccination in neoplastic disease. Ann. Int. Med. 82: 666–669.PubMedGoogle Scholar
  3. 3.
    McKhann, C. F., C. G. Hendrickson, L. E. Spitler, A. Gunnarson, D. Bannerjee, and W. R. Nelson. 1975. Immunotherapy of melanoma with BCG–two fatalities following intralesional injection. Cancer 35: 514–520.PubMedCrossRefGoogle Scholar
  4. 4.
    Florentin, I., R. Huchet, M. Bruley-Rosset, O. Halle-Pannenko and G. Mathe. 1976. Studies on the mechanism of action of BCG. Cancer Immunol. Immunother. 1: 31–39.Google Scholar
  5. 5.
    Gefford, M., and S. Orbach-Arbuoys. 1976. Enhancement of T suppressor activity in mice by high doses of BCG. Cancer Immunol. Immunother. 1: 41–45.Google Scholar
  6. 6.
    Bornstein, R. R., M. J. Mastrangelo, N. Sulit, D. Chee, J. W. Yarboro, L. Prehn, and R. J. Prehn. 1973. Immunotherapy of melanoma with intralesional BCG. Nat. Cancer Inst. Monog. 39: 213–215.Google Scholar
  7. 7.
    McLaughlin, C. A., S. M. Strain, W. D. Bickel, M. B. Goren, K. Azuma, K. Milner, J. L. Cantrell, and E. Ribi. 1978. Regression of line 10 hepatocellular carcinomas following treatment with water-soluble microbial extracts combined with trehalose or arabinose mycolates. Cancer Immunol. Immunother. 4: 61–68.Google Scholar
  8. 8.
    Milas, L., N. Hunter, and H. R. Withers. 1975. Combination of local irradiation with systemic applications of anaerobic corynebacterium in therapy of a murine fibrosarcoma. Cancer Res. 35: 1274–1277.Google Scholar
  9. 9.
    Vosika, G. J., J. Schmidtke, A. Goldman, E. Ribi, R. Parker, and G. R. Gray. 1979. Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate. Cancer 44: 495–503.PubMedCrossRefGoogle Scholar
  10. 10.
    Vosika, G. J., J. Schmidtke, A. Goldman, E. Ribi, and G. R. Gray. 1979. Phase I-II study of intralesional immunotherapy with oil-attached mycobacterium smegmatis cell wall skeleton and trehalose dimycolate. Cancer Immunol. Immunother. 6: 135–142.CrossRefGoogle Scholar
  11. 11.
    Halpern, B. (ed.). 1975. Corynebacterium parvum: Applications in experimental and clinical oncology. Plenum Press, New York.Google Scholar
  12. 12.
    Azuma, I., E. Ribi, T. J. Meyer, and B. Zbar. 1974. Biologically active components of mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J. Nat. Cancer Inst. 52: 95–101.Google Scholar
  13. 13.
    Gray, G. R., E. Ribi, D. Granger, R. Parker, I. Azuma, and K. Yamomoto. 1975. Immunotherapy of cancer: Tumor suppression and regression by cell walls of mycobacterium phlei attached to oil droplets. J. Nat. Cancer Inst. 55: 727–730.PubMedGoogle Scholar
  14. 14.
    Ribi, E., M. C. Milner, D. Granger, M. T. Kelly, K. Yamomoto, W. Brehmer, R. Parker, R. F. Smith, and S. M. Strain. 1976. Immunotherapy with non-viable microbial components. Ann. N. Y. Acad. Sci. 277: 228–238.PubMedCrossRefGoogle Scholar
  15. 15.
    Israel, L., R. Edelstein, A. DePierre, and N. Dimitrov. 1975. Daily intravenous infusion of corynebacterium parvum in twenty patients with disseminated cancer. A preliminary report of clinical and biological findings. J. Nat. Cancer Inst. 55: 29–33.PubMedGoogle Scholar
  16. 16.
    Vosika, G. J., Schmidtke, A. Goldman, E. Ribi, R. Parker, and G. R. Gray. 1978. Local and systemic immunotherapy of human cancer with mycobacterial cell wall skeleton and trehalose dimycolate (P3), p. 33–51. In E. M. Hersh, M. A. Chirigos and M. J. Mastrangelo (eds.), Augmenting agents in cancer therapy. Raven Press, New York, N. Y.Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • Gerald Vosika
    • 1
  • Tim Trenbeath
    • 1
  • Cathy Giddings
    • 1
  • Gary R. Gray
    • 2
  1. 1.The Department of MedicineUniversity of North Dakota Medical School, and the Veterans Administration HospitalFargoUSA
  2. 2.The Department of ChemistryUniversity of MinnesotaMinneapolisUSA

Personalised recommendations